Latest Cdmo News

Page 1 of 2
IDT Australia expects FY27 revenue of $19 million to $20 million and EBITDA of $1 million to $1.5 million, marking a projected swing from a $0.92 million FY26 loss. The forecast rests on larger customer contracts, a five-year radiopharmaceutical deal and roughly $7 million of manufacturing upgrades.
Victor Sage
Victor Sage
18 Nov 2026
Mayne Pharma will sell its international operations, including the Salisbury manufacturing site, to Evaris Pharma for $55.5 million in cash. The deal leaves the company focused entirely on its US Women’s Health, Dermatology and DistributeRx businesses, subject to ACCC approval.
Victor Sage
Victor Sage
6 Nov 2026
Charles River Laboratories delivered a second consecutive quarter of organic revenue growth and raised its 2026 outlook, despite reported revenue falling after divestitures. The quarter’s sharp GAAP earnings increase was heavily amplified by a US$245.6 million tax reserve reversal.
Ada Torres
Ada Torres
4 Nov 2026
Epsilon Healthcare delivered record September-quarter customer receipts of A$3.9 million, while nine-month revenue reached A$11.5 million. The growth story is strengthening, but cash fell to A$997,000 and quarterly operating cash flow remained negative.
Ada Torres
Ada Torres
30 Oct 2026
Imagion Biosystems has signed nanoComposix to resume GMP-aligned manufacturing of the MagSense nanoparticle core, a move designed to support its FDA-cleared HER2 breast cancer programme without the fixed cost of an in-house facility. The agreement improves manufacturing readiness, but its value, duration and production commitments remain undisclosed.
Victor Sage
Victor Sage
14 Sept 2026
Vitrafy Life Sciences has secured its first US cell and gene therapy foothold by deploying its cryopreservation technology at Charter Medical's Innovation Hub, signalling a strategic expansion into a high-value biopharma segment.
Ada Torres
Ada Torres
2 Sept 2026
IDT Australia reports a sharp turnaround in FY26 with a 66% reduction in net loss and an 85% improvement in EBITDA, underpinned by a strategic reset and targeted investments in manufacturing capabilities.
Victor Sage
Victor Sage
20 Aug 2026
Entropy Neurodynamics has partnered with BioCina to establish GMP manufacturing for its intravenous psilocin formulation TRP-8803, a critical step toward late-stage clinical trials and commercialisation.
Ada Torres
Ada Torres
19 Aug 2026
IDT Australia boosts its FY26 revenue guidance to $16.8 million, anticipating a substantial narrowing of EBITDA losses to under $1 million, driven by strong demand and cost efficiencies.
Ada Torres
Ada Torres
21 July 2026
INOVIQ Limited hit a roadblock in expanding clinical validation of its EXO-OC™ ovarian cancer test due to unsuitable biobank samples, yet improved its diagnostic algorithm and progressed its CAR-exosome therapeutic program, maintaining a solid cash position of A$9.35 million.
Ada Torres
Ada Torres
13 July 2026
INOVIQ Limited’s CAR-exosome platform demonstrated potent tumour-killing activity in ovarian cancer cell lines, eliminating up to 90% of cancer cells within 48 hours and reinforcing its potential against hard-to-treat solid tumours.
Ada Torres
Ada Torres
25 June 2026
Epsilon Healthcare has achieved its highest quarterly receipts ever with $3.14 million in Q1 2026, driven by strong expansion across contract manufacturing, clinics, and pharmacy operations.
Ada Torres
Ada Torres
30 Apr 2026

Browse the archive

Full archive